Sterling Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Sterling Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-249	Closed	-$5.01K	–	3353
2026 Q1	$5.01K	Sell	249 -15	-6%	-$242	﹤0.01%	2732
2025 Q4	$4.26K	Buy	264 +173	+190%	+$2.29K	﹤0.01%	2939
2025 Q3	$1.11K	Hold	91	–	–	﹤0.01%	3064
2025 Q2	$1.03K	Buy	91 +50	+122%	+$611	﹤0.01%	3057
2025 Q1	$473	Hold	41	–	–	﹤0.01%	2965
2024 Q4	$347	Buy	41 +2	+5%	+$21	﹤0.01%	3072
2024 Q3	$452	Buy	+39	New	+$491	﹤0.01%	2918

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sterling Capital Management's KALV Position: Q2 2026 in Review

Sterling Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 249 shares — an estimated $5.01K sold.

Sterling Capital Management first reported a position in KALV in Q3 2024 and held it in 7 quarters. The position peaked at $5.01K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Sterling Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sterling Capital Management sold 249 KalVista Pharmaceuticals shares in Q2 2026, an estimated $5.01K.
Sterling Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2024 and held it in 7 quarters.
Sterling Capital Management's KalVista Pharmaceuticals position peaked at $5.01K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.